Dr. John Mendelsohn served as president of The University of Texas M.D. Anderson Cancer Center from 1996 to 2011 during a period of tremendous growth in clinical and research activities, and continues as Director of the institution’s Sheikh Khalifa Institute for Personalized Cancer Therapy. He is a senior fellow in health and technology at the James A. Baker III Institute for Public Policy at Rice University and is founding chair of the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine. At the University of California, San Diego from 1970 to 1985, he was the founding director of its cancer center. At Memorial Sloan-Kettering Cancer Center from 1985 to 1996 he chaired the Department of Medicine and co-headed Molecular Pharmacology and Therapeutics. Dr. Mendelsohn’s laboratory research from 1970-1996 pioneered the now universally adopted concept of targeted anti-receptor therapy that blocks key molecular signaling pathways in cells, as a new form of cancer treatment. He has authored more than 250 scientific papers, reviews and book chapters, has received many honors and awards, was elected to the National Academy of Medicine and the American Academy of Arts and Sciences, and recently served as chairman of the Houston Grand Opera.